Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
mig [2019/07/21 22:39]
sflitman [Migraine]
mig [2020/07/15 00:39] (current)
Line 4: Line 4:
  
 ^ Condition(s)  ^ Type of Drug  ^  Phase  ^  Add-On  ^  Placebo  ^  Duration  ^  Open-Label Extension  ^  ^ Condition(s)  ^ Type of Drug  ^  Phase  ^  Add-On  ^  Placebo  ^  Duration  ^  Open-Label Extension  ^
-Abortive therapy for acute migraine | Oral combination of two approved drugs |  III  |  Yes  |  33%  |  12 weeks  |  None  |+Pediatric episodic migraine, under 15 days per month Approved Emgality monthly injection  |  III  |  Yes  |  50%  |  3 months  |  3 months 
 +| Pediatric chronic migraine, 15 or more days per month | Approved Emgality monthly injection  |  III  |  Yes  |  50%  |  3 months  |  3 months 
 +| Pediatric episodic migraine abortive therapy  |  Approved Reyvow oral drug  |  III  |  Yes  |  50%  |  24 weeks  
 +| Pediatric chronic migraine abortive therapy |  Approved Revyow oral drug   III  |  Yes  |  50% for 3 months, then 0% for 9 months  |  12 months   |  
  
 <html><!-- <html><!--
-| Treatment-resistant migraine prevention | Approved Emgality monthly injection |  III  |  Yes  |  50%  |  3 months  |  3 months  || Episodic migraine abortive therapy  |  Novel non-triptan oral agent  |  III  |  Yes  |  50%  |  24 weeks  | +
-| Episodic migraine, under 15 days per month |  Subcutaneous CGRP antagonist  |  III  |  No  |  50%  |  6 months of study agent, total duration 12 months +
-| Chronic migraine, 15 or more days per month |  Subcutaneous CGRP antagonist  |  III  |  Yes, only Topamax or Inderal permitted  |  50% for 3 months, then 0% for 9 months  |  12 months of study agent, total duration 16 months.  |  +
 --></html> --></html>
  
Line 19: Line 20:
 contact us at (855) 829-8899 or use the form below.  One of our skilled Clinical Research contact us at (855) 829-8899 or use the form below.  One of our skilled Clinical Research
 Coordinators will contact you as soon as possible.  Thank you for your interest in our research! Coordinators will contact you as soon as possible.  Thank you for your interest in our research!
-<div align=right>Stephen S. Flitman, MD, Medical Director</div> +<div align=right> 
 + <table border=0 cellspacing=0> 
 +  <tr><td>Joshua A. Tobin, MD, Director of Migraine Research</td></tr>  
 +  <tr><td>Stephen S. Flitman, MD, Medical Director</td></tr> 
 + </table>  
 +</div>
 <p>  <p> 
 <div align=center>  <div align=center> 
-<form method=post action="http://neurozone.org/cgi-n/emailform.cgi"> +<form method=post action="https://neurozone.org/cgi-n/emailform.cgi"> 
 <input type=hidden name="_site" value="Clinical Research Inquiry">  <input type=hidden name="_site" value="Clinical Research Inquiry"> 
-<input type=hidden name="_link" value="http://neurozone.org/wiki/doku.php?id=ad"> +<input type=hidden name="_link" value="https://neurozone.org/wiki/doku.php?id=ad"> 
 <input type=hidden name=trialtype value="Migraine"> <input type=hidden name=trialtype value="Migraine">
 <table border=2 cellspacing=0 cellpadding=2>  <table border=2 cellspacing=0 cellpadding=2> 
Print/export
QR Code
QR Code mig (generated for current page)